ETF盘中资讯|港股通创新药再爆发，520880冲上3.6%！机构：2026年国产创新药有望迎业绩拐点与估值重塑

Core Viewpoint - The Hong Kong stock market's innovative drug sector has shown significant growth, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 3.6% and 36 out of 37 covered companies reporting gains, indicating a strong performance in the sector [1] Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a rapid increase of over 3.6% [1] - 36 out of the 37 innovative drug companies covered by the ETF reported positive performance, with Syncona Health-B leading with a surge of over 13% [1] - Major player Kangfang Biologics saw an increase of nearly 5% [1] Group 2: Regulatory Approvals and Developments - Innovent Biologics' CTLA-4 monoclonal antibody "Daboshu" became the first domestically approved CTLA-4 inhibitor, filling a gap in the dual immune new adjuvant therapy field in China [1] - AstraZeneca and Daiichi Sankyo's TROP2 ADC "Dercutuzumab" received approval for breast cancer indications, further solidifying the advantages in the ADC sector [1] Group 3: Industry Trends and Projections - The innovative drug business development (BD) transactions are on the rise, with the total authorization amount for Chinese innovative drugs reaching $135.655 billion and 157 transactions recorded in 2025, both setting historical highs [1] - China's pipeline of new drugs now accounts for 30% of the global total, ranking second worldwide [1] - Analysts suggest that the pharmaceutical and biotechnology industry is entering a critical phase of innovation realization and global expansion, with a potential performance inflection point and valuation restructuring expected by 2026 [1][2] Group 4: Investment Strategies - Huafu Securities maintains that the long-term logic of pharmaceutical innovation remains unchanged, with the recent positive market performance indicating good opportunities for innovative drugs and devices in 2026 [2] - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has three unique advantages: pure focus on innovative drugs, significant weight on leading companies, and better risk control [2] - For investors looking to reduce volatility while still focusing on innovative drugs, the only drug ETF (562050) and its associated fund (024986) are recommended, which focus on the top 50 A-share pharmaceutical companies and include a significant portion of traditional Chinese medicine [2][3]